Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398554 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL1398584 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2DRD2 | |
| SCHEMBL1398801 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1398687 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1398708 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1398678 | 0.82 | HCRTR1 (0.55) | HCRTR1HCRTR2DRD2 | |
| SCHEMBL1398772 | 0.74 | HCRTR1 (0.51) | HCRTR1HCRTR2KDM4E | |
| SCHEMBL1340002 | 0.71 | HCRTR1 (0.54) | HCRTR1HCRTR2KDM4ELMNAHPGD | |
| SCHEMBL1398816 | 0.70 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL6820366 | 0.70 | HCRTR1 (0.59) | HCRTR1HCRTR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | claimed |
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |